Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.52 |
| ▸ | DHODH | Q02127 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1013662 | 0.84 | CNR1 (0.53) | CNR1SERPINE1DHODHMAPTALDH1A1 | |
| SCHEMBL11402843 | 0.81 | MAPT (0.63) | MAPTGPR35ALDH1A1NPC1RAB9A | |
| SCHEMBL1016958 | 0.81 | SERPINE1 (0.53) | CNR1SERPINE1DHODHMAPTGPR35 | |
| SCHEMBL1016744 | 0.80 | CNR1 (0.63) | CNR1SERPINE1GPR35 | |
| SCHEMBL11453702 | 0.77 | MAPT (0.58) | MAPTGPR35ALDH1A1NPC1RAB9A | |
| SCHEMBL1013330 | 0.75 | CNR1 (0.60) | CNR1SERPINE1KMT2A | |
| SCHEMBL11065326 | 0.74 | MAPT (0.55) | MAPTGPR35ALDH1A1NPC1RAB9A | |
| SCHEMBL11612418 | 0.74 | GPR35 (0.61) | MAPTGPR35ALDH1A1NPC1RAB9A | |
| SCHEMBL11651728 | 0.74 | HPGD (0.61) | MAPTGPR35ALDH1A1NPC1RAB9A | |
| SCHEMBL11064084 | 0.74 | MAPT (0.68) | MAPTGPR35ALDH1A1KMT2ACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415479-B2 | Inhibitor of plasminogen activator inhibitor-1 | RENASCIENCE CO., LTD. (JP) | 2013-04-09 | — | — | US | disclosed |
| US-20110112140-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | RENASCIENCE CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| EP-2272822-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | Renascience CO., LTD. (JP) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112140-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | SERPINE1, SERPINB1, SERPINC1 | CNR1 3950/4885SERPINE1 1/4885DHODH 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.